Sanofi (SNY) Equity Income (2009 - 2018)

Sanofi's (SNY) quarterly Equity Income came in at $53.7 million in Q2 2018, up 45.72% quarter-over-quarter from $36.9 million in Q1 2018.

Sanofi (SNY) Equity Income (2009 - 2018) Analysis & Trends

Sanofi has disclosed Equity Income across 6 years of filings, most recently posting $53.7 million for Q2 2018.

Equity Income for Q2 2018 came in at $53.7 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2018 was $107.5 million (changed N/A YoY), and the FY2025 annual result was -$180.4 million, down 381.41% from the prior year.
Equity Income came in at $53.7 million for Q2 2018 at Sanofi, up from $36.9 million in the prior quarter.
In the past five years, Equity Income ranged from a high of $53.7 million in Q2 2018 to a low of $36.9 million in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Gsk	93,699,046.73 Bn	93,699,041.77 Bn	7.76 Bn	-5.39 Mn
2	Eli Lilly	1,012.06 Bn	1,006.77 Bn	16.22 Bn	-
3	Johnson & Johnson	560.67 Bn	538.62 Bn	15.96 Bn	-
4	AbbVie	402.20 Bn	392.85 Bn	10.78 Bn	-
5	Merck	298.59 Bn	292.94 Bn	12.09 Bn	-
6	Amgen	188.77 Bn	176.74 Bn	5.87 Bn	-
7	Gilead Sciences	160.22 Bn	152.49 Bn	5.52 Bn	-
8	Pfizer	148.19 Bn	135.42 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	116.72 Bn	106.26 Bn	8.07 Bn	-
10	Sanofi	63.47 Mn	-6.87 Bn	9.49 Bn	-

Download Data